• ქართული
  • English
  • Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

    LONDON (Reuters) – AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

    Market Quotes by TradingView